v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of worldwide net revenues
The following table details AbbVie’s worldwide net revenues:
Three months ended
March 31,
(in millions)20262025
Immunology
SkyriziUnited States$3,775 $2,919 
International708 506 
Total$4,483 $3,425 
RinvoqUnited States$1,405 $1,220 
International714 498 
Total$2,119 $1,718 
HumiraUnited States$357 $744 
International331 377 
Total$688 $1,121 
Neuroscience
VraylarUnited States$902 $763 
International3 2 
Total$905 $765 
Botox TherapeuticUnited States$842 $723 
International167 143 
Total$1,009 $866 
UbrelvyUnited States$330 $233 
International9 7 
Total$339 $240 
QuliptaUnited States$250 $172 
International46 21 
Total$296 $193 
VyalevUnited States$89 $6 
International112 57 
Total$201 $63 
Other NeuroscienceUnited States$46 $75 
International79 80 
Total$125 $155 
Oncology
VenclextaUnited States$341 $312 
International429 353 
Total$770 $665 
Three months ended
March 31,
(in millions)20262025
ImbruvicaUnited States$332 $529 
Collaboration revenues224 209 
Total$556 $738 
Elahere
United States
$160 $165 
International
38 14 
Total$198 $179 
Epkinly
Collaboration revenues
$51 $36 
International32 15 
Total$83 $51 
Other OncologyUnited States$24 $— 
Aesthetics
Botox CosmeticUnited States$371 $295 
International297 261 
Total$668 $556 
Juvederm CollectionUnited States$85 $75 
International147 156 
Total$232 $231 
Other AestheticsUnited States$248 $270 
International38 45 
Total$286 $315 
Other Key Products
MavyretUnited States$183 $142 
International168 164 
Total$351 $306 
CreonUnited States$361 $355 
Linzess
United States$272 $139 
International11 9 
Total$283 $148 
All other$1,025 $1,253 
Total net revenues$15,002 $13,343